Table 2.
Clinical and laboratory factors as well as characteristics of study children.
| Factor | Group A Detectable Viral Load (N = 27) |
Group B Non-Detectable Viral Load (N = 74) |
p-Value |
|---|---|---|---|
| Adherence ≥ 95%, n (%) | 17 (63.0) | 65 (87.8) | 0.008 |
| Last WHO stage, n (%) | |||
| 1, 2 | 20 (74.1) | 47 (63.5) | 0.353 |
| 3, 4 | 7 (25.9) | 27 (36.5) | |
| HAART, n (%) | |||
| PI | 15 (55.6) | 37 (50.0) | 0.659 |
| Non-PI | 12 (44.4) | 37 (50.0) | |
| Nadir CD4 cell count during the study, mean ± SD, cell/µL | 646.0 ± 326.2 | 867.9 ± 341.1 | 0.025 |
| Nadir hematocrit, mean ± SD, g/dL | 37.1 ± 4.3 | 38.3 ± 3.1 | 0.222 |
| Peak cholesterol, mean ± SD, mg/dL | 186.0 ± 35.0 | 193.4 ± 37.6 | 0.478 |
| Peak triglyceride, mean ± SD, mg/dl | 135.8 ± 75.1 | 126.8 ± 59.0 | 0.608 |
| Hospitalization, n (%) | 7 (25.9) | 15 (20.3) | 0.590 |
| Pneumonia, n (%) | 5 (18.5) | 18 (24.3) | 0.604 |
| ILI, n (%) | 11 (40.7) | 13 (17.6) | 0.020 |
| OIs, n (%) | 12 (44.4) | 16 (21.6) | 0.028 |
| Study status, n (%) | |||
| Yes | 22 (81.5) | 63 (85.1) | 0.759 |
| No | 5 (18.5) | 11 (14.9) | |
| Distance of residence, n (%) | |||
| Short | 25 (92.6) | 64 (86.5) | 0.501 |
| Long | 2 (7.4) | 10 (13.5) | |
| Caregiver, n (%) | |||
| Parent | 14 (51.9) | 36 (48.6) | 0.712 |
| Relative | 11 (40.7) | 30 (40.5) | |
| Care Center | 2 (7.4) | 8 (10.8) | |
| Father as main caregiver, n (%) | 3 (11.1) | 10 (13.5) | 1.00 |
Bold data: p-values < 0.05. WHO: The World Health Organization; HAART: highly active antiretroviral therapy; ILI—influenza-like illness; OIs—opportunistic infections.